Cookie Policy - To find out more about cookies on this website, see our privacy policy

Cookie Policy

We Help Companies Find New Sales Opportunities

We Help Companies Find New Sales Opportunities


Genzyme, the pharmaceuticals firm with 300 staff in Haverhill, has been acquired by Sanofi-Aventis of France for £12bn.

Genzyme is to expand its life sciences research facility at Cambridge Science Park with an additional 10,000 sq ft of laboratory and office space.

Genzyme is to expand the 100-strong workforce at its Oxford-based biotechnology business with ten new jobs, having agreed a strategic partnership with Bayer.

Genzyme is planning to expand its pharmaceuticals factory in Haverhill, in order to increase production of the bulk polymer product for its kidney disease drug.

Genzyme of the US is to set up a biotechnology research facility in Cambridge this year, with 150 staff.

Genzyme has won US and European approval to start producing ingredients for a kidney drug at its new £55m plant in Haverhill.

Genzyme of the US is to build a £37m biotechnology production plant in Haverhill to meet rising demand for its Renegal kidney drug, with the creation of 200 jobs.

Genzyme is planning to build a £12m plant in Haverhill, Suffolk, to produce the active chemical ingredient for Renagel capsules.